SCHEMBL6835176

SCHEMBL6835176

COc1ccc2c(c1)-c1c(nc(-c3ccccc3)n1O)CCC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 5/20 0.51
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 3/20 0.44
HSD17B10 Q99714 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
MAPT P10636 1/20 0.44
CYP2C9 P11712 1/20 0.44
TSHR P16473 1/20 0.44
CYP2C19 P33261 1/20 0.44
ESR1 P03372 2/20 0.42
ACHE P22303 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TUBB4A P04350 5/20 0.40
TUBB P07437 5/20 0.40
TUBA3C P0DPH7 5/20 0.40
TUBA1B P68363 5/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6835181 0.93 NPY5R (0.49) NPY5RKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6831681 0.90 NPY5R (0.52) NPY5RKDM4EALDH1A1HPGDCYP3A4
SCHEMBL6835218 0.88 NPY5R (0.55) NPY5RCYP3A4CYP2C9
SCHEMBL6836913 0.85 NPY5R (0.55) NPY5RMEN1KMT2AMAP3K5
SCHEMBL6834506 0.82 NPY5R (0.48) NPY5RKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6831686 0.81 KDM4E (0.48) NPY5RKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6835192 0.75 NPY5R (0.50) NPY5RALDH1A1
SCHEMBL6835215 0.74 NPY5R (0.53) NPY5RKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6831684 0.73 NPY5R (0.45) NPY5RKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6567519 0.72 NPY5R (0.49) NPY5RKDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040198791-A1 Fused imidazole derivative FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198791-A1 Fused imidazole derivative H1-0, H1-5, H1-3 NPY5R 983/4885KDM4E 3547/4885ALDH1A1 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.